{"id":51380,"date":"2022-11-30T12:02:44","date_gmt":"2022-11-30T11:02:44","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/ahf-opposes-creation-of-splinter-340b-drug-discount-program\/"},"modified":"2022-11-30T12:02:44","modified_gmt":"2022-11-30T11:02:44","slug":"ahf-opposes-creation-of-splinter-340b-drug-discount-program","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/ahf-opposes-creation-of-splinter-340b-drug-discount-program\/","title":{"rendered":"AHF Opposes Creation of Splinter 340B Drug Discount Program"},"content":{"rendered":"
\n

\n\u2018340C\u2019 program would weaken public health providers\u2019 ability to fight drug industry greed<\/i>\n<\/p>\n

WASHINGTON–(BUSINESS WIRE)–AIDS Healthcare Foundation (AHF<\/a>) opposes the creation of a new drug discount program, \u201c340C,\u201d for non-hospital community health providers. The push for the new federal program stems from unlawful efforts of drug companies to disable an already existing program, the 340B Drug Pricing Program<\/a>, which has protected public health for 30 years. Instead of aiding drug company priorities, 340B entities – which comprise the public health safety net in this country – must continue to work together to strengthen and protect the 340B program.\n<\/p>\n

\nThirty years ago, Congress created the 340B Program to help nonprofit health providers like charity hospitals and community clinics \u201cstretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.\u201d Under 340B, drug companies voluntarily provide discounts to nonprofit providers to gain access to the very profitable Medicaid and Medicare programs. Nonprofit providers use these discounts to provide more and better services to vulnerable patients. The voluntary program greatly benefits the drug industry. Yet, drug companies continue to attack the program to avoid providing discounts.\n<\/p>\n

\nDrug companies\u2019 latest attack attempts to unlawfully limit where 340B eligible patients can obtain drugs. By limiting the number of eligible pharmacies, drug makers aim to provide fewer discounts to covered entities. The unlawful practice is the subject of numerous lawsuits. Meanwhile, smaller 340B nonprofits face financial hardship from reduced discounts. To avoid harm, some providers hope to create a new program – 340C – to insulate themselves from drug company greed. Their hope is misplaced.\n<\/p>\n

\n\u201cIf there is one thing we have learned, it\u2019s that there is no end to drug industry greed. A new program will not stop industry efforts to eliminate discounts to increase profits. AHF urges 340B providers not to fall for the drug industry\u2019s \u2018divide-and-conquer\u2019 trap,\u201d said Tom Myers<\/b>, AHF General Counsel.\n<\/p>\n

\nAHF is the largest nonprofit providing HIV\/AIDS and STD treatment and care in 16 states, the District Columbia, and Puerto Rico, and has been a 340B participant for nearly twenty years.\n<\/p>\n

\nAIDS Healthcare Foundation (AHF)<\/b>, the largest global AIDS organization, currently provides medical care and\/or services to over 1.7 million people in 45 countries worldwide in the US, Africa, Latin America\/Caribbean, the Asia\/Pacific Region and Eastern Europe. To learn more about AHF, please visit our website: www.aidshealth.org<\/a>, find us on Facebook: www.facebook.com\/aidshealth<\/a> and follow us on Twitter: @aidshealthcare<\/a> and Instagram: @aidshealthcare<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nWASHINGTON<\/b>
John Hassell, <\/b>National Director of Advocacy, AHF
\n
+1.202.774.4854 [cell]<\/b> John.hassell@aidshealth.org<\/a>\n<\/p>\n

\nLOS ANGELES<\/b>
Ged Kenslea, <\/b>Senior Director, Communications, AHF
\n
+1.323.791.5526 [cell]<\/b> gedk@aidshealth.org<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u2018340C\u2019 program would weaken public health providers\u2019 ability to fight drug industry greed WASHINGTON–(BUSINESS WIRE)–AIDS Healthcare Foundation (AHF) opposes the creation of a new drug discount program, \u201c340C,\u201d for non-hospital community health providers. The push for the new federal program stems from unlawful efforts of drug companies to disable an already existing program, the 340B … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51380","6":"format-standard","7":"category-industry"},"yoast_head":"\nAHF Opposes Creation of Splinter 340B Drug Discount Program - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/ahf-opposes-creation-of-splinter-340b-drug-discount-program\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AHF Opposes Creation of Splinter 340B Drug Discount Program - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"\u2018340C\u2019 program would weaken public health providers\u2019 ability to fight drug industry greed WASHINGTON–(BUSINESS WIRE)–AIDS Healthcare Foundation (AHF) opposes the creation of a new drug discount program, \u201c340C,\u201d for non-hospital community health providers. The push for the new federal program stems from unlawful efforts of drug companies to disable an already existing program, the 340B ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/ahf-opposes-creation-of-splinter-340b-drug-discount-program\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-30T11:02:44+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ahf-opposes-creation-of-splinter-340b-drug-discount-program\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ahf-opposes-creation-of-splinter-340b-drug-discount-program\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"AHF Opposes Creation of Splinter 340B Drug Discount Program\",\"datePublished\":\"2022-11-30T11:02:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ahf-opposes-creation-of-splinter-340b-drug-discount-program\\\/\"},\"wordCount\":451,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ahf-opposes-creation-of-splinter-340b-drug-discount-program\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ahf-opposes-creation-of-splinter-340b-drug-discount-program\\\/\",\"name\":\"AHF Opposes Creation of Splinter 340B Drug Discount Program - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-11-30T11:02:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ahf-opposes-creation-of-splinter-340b-drug-discount-program\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ahf-opposes-creation-of-splinter-340b-drug-discount-program\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ahf-opposes-creation-of-splinter-340b-drug-discount-program\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AHF Opposes Creation of Splinter 340B Drug Discount Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AHF Opposes Creation of Splinter 340B Drug Discount Program - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/ahf-opposes-creation-of-splinter-340b-drug-discount-program\/","og_locale":"en_US","og_type":"article","og_title":"AHF Opposes Creation of Splinter 340B Drug Discount Program - Pharma Trend","og_description":"\u2018340C\u2019 program would weaken public health providers\u2019 ability to fight drug industry greed WASHINGTON–(BUSINESS WIRE)–AIDS Healthcare Foundation (AHF) opposes the creation of a new drug discount program, \u201c340C,\u201d for non-hospital community health providers. The push for the new federal program stems from unlawful efforts of drug companies to disable an already existing program, the 340B ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/ahf-opposes-creation-of-splinter-340b-drug-discount-program\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-30T11:02:44+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/ahf-opposes-creation-of-splinter-340b-drug-discount-program\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/ahf-opposes-creation-of-splinter-340b-drug-discount-program\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"AHF Opposes Creation of Splinter 340B Drug Discount Program","datePublished":"2022-11-30T11:02:44+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ahf-opposes-creation-of-splinter-340b-drug-discount-program\/"},"wordCount":451,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/ahf-opposes-creation-of-splinter-340b-drug-discount-program\/","url":"https:\/\/pharma-trend.com\/en\/ahf-opposes-creation-of-splinter-340b-drug-discount-program\/","name":"AHF Opposes Creation of Splinter 340B Drug Discount Program - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-11-30T11:02:44+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/ahf-opposes-creation-of-splinter-340b-drug-discount-program\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/ahf-opposes-creation-of-splinter-340b-drug-discount-program\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/ahf-opposes-creation-of-splinter-340b-drug-discount-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"AHF Opposes Creation of Splinter 340B Drug Discount Program"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51380","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51380"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51380\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51380"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51380"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51380"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}